Table 3.
Comorbidities, COVID-19 infection, and vaccination status of patients with new-onset seizures.
| New-onset seizures during the first month after vaccination | |||
|---|---|---|---|
| n = 15 (%) | |||
| Sex | Male | 7 (47.0%) | |
| Female | 8 (53.0%) | ||
| Mean age (SD) | 65.8 (21.7) | ||
| Seizure type | Focal aware | 1 (6.7%) | |
| Focal impaired awareness | 4 (26.7%) | ||
| Focal to bilateral tonic-clonic | 5 (33.3%) | ||
| Generalized tonic-clonic with unknown onset | 5 (33.3%) | ||
| Status epilepticus | 5 (33.0%) | ||
| Cluster of seizures | 3 (20.0%) | ||
| Comorbidities | Hypertension | 8 (53.3%) | |
| Diabetes mellitus | 7 (46.6%) | ||
| Dyslipidemia | 8 (53.3%) | ||
| Neoplastic disease | 4 (26.6%) | ||
| Pneumological disease | 2 (13.3%) | ||
| Neurological disease (different from epilepsy) | 9 (60.0%) | ||
| Cardiological disease | 5 (33.3%) | ||
| Immunosuppression | 0 | ||
| History of a positive test for SARS-CoV-2 | 4 (26.6%) | ||
| Vaccine type and dose before seizure | Pfizer | 1st dose | 5 (33.3%) |
| 2nd dose | 7 (47.0%) | ||
| Moderna | 1st dose | 0 | |
| 2nd dose | 3 (20.0%) | ||
| AZ | 1st dose | 0 | |
| 2nd dose | 0 | ||
| Jansen | 1st dose | 0 | |
| 2nd dose- booster | 0 | ||
AZ: AstraZeneca. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.